Holen Sie sich die Stockscreener-App
1.55
1.97%
0.03
Handel nachbörslich:
1.55
Schlusskurs vom Vortag:
$1.52
Offen:
$1.52
24-Stunden-Volumen:
911
Relative Volume:
0.06
Marktkapitalisierung:
$48.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-0.6152
EPS:
-2.5197
Netto-Cashflow:
-
1W Leistung:
-1.27%
1M Leistung:
+5.44%
6M Leistung:
-25.57%
1J Leistung:
-57.30%
1-Tages-Spanne:
$1.52
$1.55
1-Wochen-Bereich:
$1.50
$1.5506
52-Wochen-Spanne:
$1.10
$3.89
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Firmenname
Adlai Nortye Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ANL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
1.55 | 57.93M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Aktie (ANL) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Adlai Nortye Ltd. Announces 2025 Share Incentive Plan and Board Changes - TipRanks
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Adlai Nortye (NASDAQ:ANL) Trading Down 5.5% – Here’s What Happened - Defense World
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS By Investing.com - Investing.com South Africa
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS - Investing.com
Adlai Nortye Discontinues Buparlisib Development After Phase III Trial Results - TipRanks
ANL stock touches 52-week low at $1.71 amid sharp annual decline - Investing.com India
ANL stock touches 52-week low at $1.71 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline - Investing.com India
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline By Investing.com - Investing.com South Africa
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline - Investing.com India
Adlai Nortye Announces Change in Auditing Firm - TipRanks
Adlai Nortye Announces CFO Transition with Interim Appointment - TipRanks
Adlai Nortye stock strengthened by oncology trial results, H.C. Wainwright keeps at Buy list - Investing.com India
Adlai Nortye IPO gives old Novartis cancer drug new life - BioPharma Dive
Adlai Nortye Announces 2.5M ADS IPO at $23/sh - Investing.com
CRVO Stock Quote Price and Forecast - CNN
Finanzdaten der Adlai Nortye Ltd Adr-Aktie (ANL)
Es liegen keine Finanzdaten für Adlai Nortye Ltd Adr (ANL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):